NCT02584686View on ClinicalTrials.gov

Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Vasculogenic Erectile Dysfunction
Interventions
DRUG

Botulinum Toxin Type A

The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.

DRUG

Normal Saline

The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.

Trial Locations (1)

11321

Cairo University Hospitals, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT02584686 - Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction | Biotech Hunter | Biotech Hunter